Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Optimed Research

Neither a doctor nor a teaching hospital

Research payments

$1,333,821

255 payments

Through program year 2025, Optimed Research is reported as receiving $1,333,821 in research payments, across 255 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $115,729 13
2024 Research $229,329 26
2023 Research $162,128 14
2022 Research $37,903 15
2021 Research $387,023 80
2020 Research $391,202 104
2019 Research $10,507 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $720,962 173 payments
  2. Celgene Corporation $237,024 8 payments
  3. Novartis Pharmaceuticals Corporation $91,853 7 payments
  4. GlaxoSmithKline, LLC. $60,673 14 payments
  5. Grifols Biologicals LLC $54,360 3 payments
  6. Acrotech Biopharma LLC $43,090 9 payments
  7. Octapharma USA, Inc. $39,789 20 payments
  8. Grifols Therapeutics LLC $16,084 4 payments
  9. ACADIA Pharmaceuticals Inc $13,603 3 payments
  10. AstraZeneca Pharmaceuticals LP $13,278 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients $90,761 10 payments
  2. Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $87,076 2 payments
  3. M14-675 $75,775 7 payments
  4. M14-234 $67,329 17 payments
  5. Phase 1 Drug Interaction (AKA IM042-002) (EOE) $62,189 3 payments
  6. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $60,673 14 payments
  7. An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinsons Disease $56,537 7 payments
  8. A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY plus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia $55,810 4 payments
  9. M16-100 $53,713 15 payments
  10. M16-006 $51,792 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record